Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech’s 340B Discounts Making Their Mark On Product Pricing

Executive Summary

Genentech’s 340B drugs discounts totaled $1 billion in 2012 and are growing at 20% to 25% a year, a level that has prompted management to sit up and take notice, including setting up a team to work with 340B health care providers on compliance.

Advertisement

Related Content

340B Impact: Roche Starts Educating Investors About Discount
Genentech Pioneers Manufacturer Audits Of 340B Entities
340B Drug Audits: HRSA Reviewing 51 Entities In 2012

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS055493

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel